# CENTAURUS (NCT02316106)

> A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: daratumumab
- Indication: intermediate-risk or high-risk smoldering multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02316106
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: daratumumab; daratumumab; daratumumab
- Enrollment: 123
- Primary outcome: Percentage of Participants Who Achieved a Complete Response (CR) by International Myeloma Working Group (IMWG) Criteria
- Primary outcome: Progressive Disease or Death Rate

## Indexed commentary on CENTAURUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 21
- YouTube: 7
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=centaurus-nct02316106

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02316106", "email": "<work email>"}; the inbox owner confirms by the emailed link.